GlassScriptPhysician profile
Kimberly Raenell Powers
NPI 1447913736
$4,096.96
in general payments reported to CMS, 2019-2025
31 companies · $956 in 2025
The $956 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.89 · 2023: $693 · 2024: $2,433 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186 · Travel and Lodging: $711 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.43 |
| Travel and Lodging | $710.66 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $830.04 | 2024 | Ams 700 |
| Janssen Biotech, INC. | $640.06 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Accord Healthcare, INC. | $381.67 | 2023-2025 | |
| Dexcom, INC. | $275.10 | 2023 | Dexcom G7 Gss (161) |
| Endo USA, INC. | $259.35 | 2024-2025 | Aveed, Xiaflex |
| Endo Pharmaceuticals INC. | $257.12 | 2023-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $205.19 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar, INC. | $175.82 | 2024-2025 | Eligard, Jatenzo |
| Tempus Ai, INC | $141.55 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.21 | 2023-2025 | |
| Antares Pharma, INC. | $101.07 | 2024-2025 | Xyosted, Tlando |
| 180 Medical, INC. | $83.31 | 2024 | |
| Progenics Pharmaceuticals, INC. | $67.28 | 2024 | |
| Pfizer INC. | $61.04 | 2025 | |
| Verity Pharmaceuticals INC. | $56.25 | 2024 | Trelstar |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $48.82 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $47.02 | 2024-2025 | Keytruda, Welireg |
| Sun Pharmaceutical Industries INC. | $42.52 | 2024-2025 | |
| Astellas Pharma US INC | $40.34 | 2024 | Xtandi |
| Dentsply Ih Ab | $32.84 | 2024 | Lofric |
| Dendreon Pharmaceuticals LLC | $32.64 | 2025 | Provenge |
| Abbvie INC. | $32.35 | 2024 | |
| Immunitybio, INC. | $27.42 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $26.42 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.16 | 2023 | Lynparza |
| Ferring Pharmaceuticals INC. | $19.50 | 2024 | Adstiladrin |
| Urogen Pharma, INC. | $19.32 | 2024 | |
| Cycle Pharmaceuticals INC | $19.18 | 2025 | Venxxiva |
| Myriad Genetic Laboratories, INC. | $17.21 | 2025 | Prolaris |
| Smith+Nephew, INC. | $14.89 | 2021 | |
| Organogenesis INC. | $13.27 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.